• top_image

Supreme Court to hear case against BRCA1 & BRCA2 patents

December 5, 2012

The Supreme Court will hear arguments challenging the patents of 2 genes associated with breast and ovarian cancer - the BRCA1 and BRCA2 genetic mutations, which are currently owned by Myriad Laboratories. The lawsuit charges the patents stifle diagnostic testing and research that could lead to cures and limit a woman’s medical options. The Alliance has joined the suit; the ACLU and Public Patent Foundation first filed it in 2009.<link href="http://www.reuters.com/article/2012/11/30/us-usa-court-genes-idUSBRE8AT19620121130">Reuters article</link><link href="http://www.aclu.org/free-speech/supreme-court-hear-case-challenging-patents-breast-and-ovarian-cancer-genes">ACLU Press Release</link>

The Supreme Court will hear arguments challenging the patents of 2 genes associated with breast and ovarian cancer - the BRCA1 and BRCA2 genetic mutations, which are currently owned by Myriad Laboratories. The lawsuit charges the patents stifle diagnostic testing and research that could lead to cures and limit a woman’s medical options. The Alliance has joined the suit; the ACLU and Public Patent Foundation first filed it in 2009.
<link href="http://www.reuters.com/article/2012/11/30/us-usa-court-genes-idUSBRE8AT19620121130">Reuters article</link>
<link href="http://www.aclu.org/free-speech/supreme-court-hear-case-challenging-patents-breast-and-ovarian-cancer-genes">ACLU Press Release</link>

Back